Can Swiss Rockets’ new CoolMPS deal with MGI Tech make Europe a genomics powerhouse?

Swiss Rockets AG, headquartered in Basel, Switzerland, has signed a landmark licensing agreement with MGI Tech Co., Ltd. and its subsidiary Complete Genomics Inc., giving the company an exclusive, perpetual right to develop, manufacture, and commercialize the next-generation CoolMPS sequencing platform. The license covers the United States, Europe, Latin America, Africa, and Central Asia, with an option to extend into the Asia-Pacific region in 2026. The deal also includes payments tied to technology transfer and future revenue-based royalties, positioning Swiss Rockets as one of the few European firms to hold such comprehensive sequencing technology rights.

The transaction signals a strategic shift for Swiss Rockets, best known for nurturing oncology and precision therapeutics startups. By acquiring CoolMPS licensing rights, the company is expanding its footprint from drug innovation into sequencing infrastructure, effectively connecting the worlds of diagnostics and therapeutics under one business model. In doing so, Swiss Rockets enters a competitive market dominated by American and Chinese players such as Illumina Inc. and BGI Group, bringing a European counterweight to the global genomics landscape.

Why did Swiss Rockets pursue MGI Tech’s CoolMPS technology now?

The timing of this partnership reflects a confluence of economic, technological, and scientific imperatives. Over the past five years, sequencing costs have dropped precipitously, but affordability has not always equated to accuracy. Many research and clinical institutions still face high error rates in variant detection, particularly in cancer diagnostics and rare disease sequencing. MGI Tech’s CoolMPS chemistry addresses these concerns by enabling longer, more precise read lengths of 600 to 700 bases, while maintaining Sanger sequencing-level quality.

For Swiss Rockets, this technology represents a foundational layer for its “omics for all” vision, a strategy that extends beyond oncology into preventive medicine, molecular diagnostics, and personalized health monitoring. The company’s leadership, including Founder and Chief Executive Officer Dr. Vladimir Cmiljanovic, described the agreement as a perfect complement to its existing portfolio of precision medicine ventures. The combination of therapeutics expertise and advanced sequencing infrastructure enables Swiss Rockets to build vertically integrated pathways from early detection to treatment optimization.

From MGI Tech’s standpoint, the partnership opens a valuable commercialization channel outside China. It allows MGI and Complete Genomics to monetize their intellectual property while focusing internal resources on research and technology refinement. For MGI, this also serves as a form of geopolitical diversification, granting market access in regions where Chinese-origin sequencing equipment faces regulatory or data governance barriers.

What makes CoolMPS sequencing unique in the global genomics market?

CoolMPS, short for Cool Molecular Probe Sequencing, is MGI Tech’s patented chemistry that substitutes the fluorescently labeled nucleotides used in conventional sequencing-by-synthesis with unmodified natural nucleotides. Instead, fluorescently labeled antibodies detect incorporated bases, reducing sequencing artifacts and improving read fidelity. The result is longer, more accurate reads that minimize false positives in variant calling and structural variation analysis.

In practical terms, this innovation enhances the accuracy of genome assembly, transcriptomics, and microbiome studies while enabling more reliable detection of somatic mutations. For clinical applications, the reduced error rate can significantly improve outcomes in early cancer detection, minimal residual disease tracking, and hereditary disease testing. Swiss Rockets has indicated that its next-generation CoolMPS systems will also integrate proprietary read-barcoding methods, expanding applications in whole-genome, transcriptome, and microbiome sequencing.

The first CoolMPS sequencers featuring SE600+ read capability are slated for early-access release in the first quarter of 2026. These systems will power products such as CompleteWGS, CompleteTranscriptome, and CompleteMicrobiome, offering a portfolio approach similar to what Illumina achieved with its NovaSeq platform, but at a potentially lower total cost of ownership.

How does this license reshape Swiss Rockets’ business model?

Before the agreement, Swiss Rockets operated primarily as an incubator and accelerator focused on therapeutic innovation. Its portfolio included pre-clinical and clinical programs in radioligand therapies, small molecules, and vaccines, many of which have attracted interest from major pharmaceutical companies. The acquisition of CoolMPS licensing rights transforms this model into a vertically integrated genomics enterprise capable of producing both the tools and the treatments of modern precision healthcare.

This hybrid positioning allows Swiss Rockets to capture value across multiple layers of the healthcare value chain, from discovery and diagnostics to treatment and long-term health management. The recurring revenue potential from sequencing consumables also introduces a new financial dynamic: stable, high-margin cash flows complementing the inherently high-risk biotech pipeline. However, the transition also brings operational challenges, such as scaling manufacturing, securing regulatory approvals, and building service and distribution networks across continents.

If successful, this model could mirror how Illumina evolved from an instrument manufacturer into a healthcare data company. It also suggests a potential European analog to the integrated ecosystem strategies seen in Asia, where firms like BGI and MGI pair hardware innovation with applied research and clinical solutions.

What are the broader industry implications of this deal?

The licensing arrangement between Swiss Rockets and MGI Tech reflects a growing trend in the life sciences industry: the shift from ownership-based R&D to partnership-driven commercialization. In recent years, several major sequencing firms have adopted similar models, granting regional licenses to local partners to navigate regulatory complexities and speed up market access. By localizing commercial operations, companies can adapt to region-specific privacy laws, data transfer restrictions, and reimbursement frameworks.

From a macroeconomic standpoint, the deal also highlights Europe’s increasing strategic interest in retaining autonomy in genomic infrastructure. With Illumina’s dominance waning amid antitrust concerns and BGI’s restricted access to Western markets, European entities have sought new avenues to secure advanced sequencing capabilities. Swiss Rockets’ deal with MGI Tech may therefore carry significance beyond commercial ambition; it can be interpreted as part of a larger trend toward regional diversification of biotechnology infrastructure.

Moreover, the agreement could accelerate the democratization of omics data. Affordable, high-fidelity sequencing enables early-detection initiatives and preventive healthcare models that reduce long-term medical costs. This aligns with the European Union’s policy emphasis on personalized medicine for all, making Swiss Rockets’ expansion both economically and socially aligned with regional healthcare priorities.

 

What risks and challenges could affect execution?

Despite the optimistic outlook, executing a multi-regional sequencing rollout is far from straightforward. Swiss Rockets will need to establish manufacturing facilities or partnerships capable of meeting global demand while ensuring compliance with complex regulatory requirements such as FDA 510(k), CE-IVD, and ISO 13485 certifications. Quality control, reagent production, and post-sale service networks will all be critical to success.

Competition will also be intense. Illumina, Thermo Fisher Scientific, Oxford Nanopore Technologies, and Pacific Biosciences each command significant market share with well-established customer ecosystems. To gain traction, Swiss Rockets must differentiate on cost efficiency, sequencing accuracy, and application diversity. Any delays in technology transfer or manufacturing could give competitors additional time to consolidate market share.

Another key consideration involves data sovereignty. Because MGI Tech originates from China, some Western governments have historically scrutinized Chinese genomics technologies due to privacy and national security concerns. Although Swiss Rockets operates independently under Swiss law, geopolitical tensions could still influence procurement decisions or funding access in sensitive markets.

Finally, scaling from a therapeutics incubator to a hardware and consumables manufacturer will test Swiss Rockets’ organizational adaptability. Maintaining R&D intensity while managing logistics, distribution, and customer support across multiple continents will require significant capital, talent, and strategic discipline.

How is the industry reacting, and what could come next?

Market observers view the licensing arrangement as strategically sound but operationally ambitious. Analysts point out that MGI Tech benefits immediately by securing royalty income and Western market penetration without geopolitical friction, while Swiss Rockets gains a technological advantage that could underpin its transition into a full-spectrum precision medicine company.

Early reactions from industry forums and investor circles have been cautiously optimistic. While Swiss Rockets is privately held, sentiment surrounding the deal has buoyed interest in European genomics ventures. MGI Tech’s stock performance in China improved modestly following the announcement, reflecting investor confidence in its ability to expand revenue through licensing rather than direct export.

The key milestones to watch over the next year include the completion of technology transfer, early-access launch of CoolMPS sequencers, and initial adoption metrics among European clinical research centers. Should the first-generation products meet expectations, Swiss Rockets could seek strategic partnerships or additional funding to accelerate commercial rollout ahead of its planned 2026 Asia-Pacific expansion.

How could Swiss Rockets’ CoolMPS partnership reshape Europe’s leadership in precision medicine and genomics innovation?

From an analytical perspective, Swiss Rockets’ move represents a bold but calculated evolution. The company is entering a capital-intensive industry that historically rewards scale, yet its timing and technology choice suggest careful strategic foresight. CoolMPS sits at the intersection of cost efficiency and accuracy—two metrics that define market success in sequencing. If Swiss Rockets can sustain technological leadership while controlling manufacturing costs, it could become one of Europe’s most influential life-sciences companies in the next decade.

The integration of multi-omics platforms into its precision medicine ecosystem could also position Swiss Rockets as a future consolidator in the diagnostics and healthtech sectors. However, to maintain investor confidence, the company must demonstrate near-term operational milestones and proof of adoption before pursuing further expansions.

In essence, this partnership is not just a commercial agreement but a signal that the global genomics race is entering a new phase—one defined by regional collaboration, affordability, and integration between sequencing, analytics, and therapeutics. If Swiss Rockets delivers on its promise, CoolMPS could become the catalyst for a new era of European-led precision medicine innovation.

What are the key takeaways from Swiss Rockets AG’s strategic CoolMPS license

• Swiss Rockets AG secured an exclusive, perpetual license for MGI Tech’s CoolMPS sequencing platform across the United States, Europe, Latin America, Africa, and Central Asia.

• The agreement includes payments tied to technology transfer and royalties, with an option to expand rights into the Asia-Pacific region in 2026.

• CoolMPS sequencing enables longer, more accurate reads and reduces sequencing errors, offering advantages for whole-genome, transcriptome, and microbiome applications.

• The first CoolMPS instruments are expected to launch in early 2026, expanding Swiss Rockets’ operations from therapeutic incubation to sequencing hardware and consumables.

• The partnership positions Swiss Rockets as a new European player in the genomics infrastructure market, competing with Illumina, Thermo Fisher Scientific, and Oxford Nanopore Technologies.

• Analysts view the deal as a bold but strategically sound expansion that could reshape Europe’s role in global precision medicine if operational execution succeeds.